MicroRNA-21 as an indicator of aggressive phenotype in breast cancer - PubMed (original) (raw)
doi: 10.1159/000348678. Epub 2013 Feb 21.
Affiliations
- PMID: 23485999
- DOI: 10.1159/000348678
MicroRNA-21 as an indicator of aggressive phenotype in breast cancer
Alpaslan Ozgün et al. Onkologie. 2013.
Abstract
Objective: The recently discovered microRNAs (miRNAs) are non-protein-coding, endogenous small RNAs. The aim of this study was to investigate the relationship between microRNA-21 (miR-21) and the clinicopathological features of breast cancer.
Materials and methods: Formalin-fixed, paraffin-embedded (FFPE) tissue samples were collected from 15 patients who had undergone surgery for primary breast cancer. The miR-21 expression levels in normal and cancer tissues were analyzed using real-time quantitative reverse transcriptase polymerase chain reaction (real-time qRT-PCR). The correlations between the miR-21 expression level and the stage of disease, the tumor size, lymph node involvement, hormone receptor status, human epidermal growth factor receptor 2 (HER2) status, and disease-free survival (DFS) were investigated.
Results: The miR-21 expression levels were significantly higher in patients with stage III disease, patients with more than 3 axillary lymph node metastases and HER2-positive patients than in patients with stage I-II disease, patients with 1-3 axillary lymph node metastases and HER2-negative patients (p = 0.005, p = 0.037, and p = 0.014, respectively). Patients with high miR-21 expression level had a significantly shorter DFS than patients with low miR-21 expression level (median DFS: 18 and 56 months, respectively; p = 0.004).
Conclusion: These results show that miR-21 is an indicator of an aggressive breast cancer phenotype and that it may be a new therapeutic target in the treatment of breast cancer in the future.
Copyright © 2013 S. Karger AG, Basel.
Comment in
- microRNA-21 and its emerging role in tumor progression in systemic malignancies.
Kapoor S. Kapoor S. Onkologie. 2013;36(7-8):451. doi: 10.1159/000353693. Epub 2013 Jun 28. Onkologie. 2013. PMID: 23921766 No abstract available.
Similar articles
- High miR-21 expression in breast cancer associated with poor disease-free survival in early stage disease and high TGF-beta1.
Qian B, Katsaros D, Lu L, Preti M, Durando A, Arisio R, Mu L, Yu H. Qian B, et al. Breast Cancer Res Treat. 2009 Sep;117(1):131-40. doi: 10.1007/s10549-008-0219-7. Epub 2008 Oct 19. Breast Cancer Res Treat. 2009. PMID: 18932017 - Clinicopathological and prognostic significance of microRNA-107 and its relationship to DICER1 mRNA expression in gastric cancer.
Inoue T, Iinuma H, Ogawa E, Inaba T, Fukushima R. Inoue T, et al. Oncol Rep. 2012 Jun;27(6):1759-64. doi: 10.3892/or.2012.1709. Epub 2012 Mar 7. Oncol Rep. 2012. PMID: 22407237 - [Serum miR-103 as a potential diagnostic biomarker for breast cancer].
Wang X, Wu X, Yan L, Shao J. Wang X, et al. Nan Fang Yi Ke Da Xue Xue Bao. 2012 May;32(5):631-4. Nan Fang Yi Ke Da Xue Xue Bao. 2012. PMID: 22588912 Chinese. - [Correlation of miR-195 with invasiveness and prognosis of breast cancer].
Song CG, Wu XY, Wang C, Fu FM, Shao ZM. Song CG, et al. Zhonghua Wai Ke Za Zhi. 2012 Apr;50(4):353-6. Zhonghua Wai Ke Za Zhi. 2012. PMID: 22800791 Chinese. - Distinct expressions of microRNAs that directly target estrogen receptor α in human breast cancer.
Yoshimoto N, Toyama T, Takahashi S, Sugiura H, Endo Y, Iwasa M, Fujii Y, Yamashita H. Yoshimoto N, et al. Breast Cancer Res Treat. 2011 Nov;130(1):331-9. doi: 10.1007/s10549-011-1672-2. Epub 2011 Jul 14. Breast Cancer Res Treat. 2011. PMID: 21755340
Cited by
- The expression and significance of five types of miRNAs in breast cancer.
Min W, Wang B, Li J, Han J, Zhao Y, Su W, Dai Z, Wang X, Ma Q. Min W, et al. Med Sci Monit Basic Res. 2014 Jul 21;20:97-104. doi: 10.12659/MSMBR.891246. Med Sci Monit Basic Res. 2014. PMID: 25047098 Free PMC article. - Triple-negative and luminal A breast tumors: differential expression of miR-18a-5p, miR-17-5p, and miR-20a-5p.
Calvano Filho CM, Calvano-Mendes DC, Carvalho KC, Maciel GA, Ricci MD, Torres AP, Filassi JR, Baracat EC. Calvano Filho CM, et al. Tumour Biol. 2014 Aug;35(8):7733-41. doi: 10.1007/s13277-014-2025-7. Epub 2014 May 9. Tumour Biol. 2014. PMID: 24810926 - miR-21 Expression in Cancer Cells may Not Predict Resistance to Adjuvant Trastuzumab in Primary Breast Cancer.
Nielsen BS, Balslev E, Poulsen TS, Nielsen D, Møller T, Mortensen CE, Holmstrøm K, Høgdall E. Nielsen BS, et al. Front Oncol. 2014 Aug 15;4:207. doi: 10.3389/fonc.2014.00207. eCollection 2014. Front Oncol. 2014. PMID: 25177545 Free PMC article. - Higher expression of circulating miR-182 as a novel biomarker for breast cancer.
Wang PY, Gong HT, Li BF, Lv CL, Wang HT, Zhou HH, Li XX, Xie SY, Jiang BF. Wang PY, et al. Oncol Lett. 2013 Dec;6(6):1681-1686. doi: 10.3892/ol.2013.1593. Epub 2013 Sep 24. Oncol Lett. 2013. PMID: 24260062 Free PMC article. - ER Negative Breast Cancer and miRNA: There Is More to Decipher Than What the Pathologist Can See!
Chamandi G, El-Hajjar L, El Kurdi A, Le Bras M, Nasr R, Lehmann-Che J. Chamandi G, et al. Biomedicines. 2023 Aug 18;11(8):2300. doi: 10.3390/biomedicines11082300. Biomedicines. 2023. PMID: 37626796 Free PMC article. Review.
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Medical
Research Materials
Miscellaneous